| Autor: |
Gitsham, A., Mack, Lucy, Shemilt, K., McCloskey, A., Gibson, J. |
| Předmět: |
|
| Zdroj: |
Journal of Oncology Pharmacy Practice; 2023 Supplement, Vol. 29, p29-30, 2p |
| Abstrakt: |
Introduction: Breast cancer in patients who are premenopausal is rare when compared to diagnosis post-menopause. A multidisciplinary management approach is taken for each patient, and their treatment plan is very specific to the cancer type. Treatment can result in various side effects such as weight fluctuation which is commonly listed. Theoretically, weight change is associated with an increased risk of developing cancer, as well as the patient having a relapse, therefore close attention must be paid by the cancer specialist team to counsel patients who are most likely at risk. Multiple factors such as patient categoric BMI at baseline, comorbidities, adjuvant therapy, and age influence a patient’s weight and any significant decrease or increase in this. Objectives: To investigate whether there is a significant change in both premenopausal and perimenopausal women patients’ weight undergoing Goserelin treatment over the course of 36 cycles of treatment. Method: NHS Foundation Trust X provided raw data (N = 46) to audit weight variation in postmenopausal women receiving Goserelin as part of their first-line adjuvant treatment for advanced ER+ who had completed 36 cycles (January 2018 – October 2021). The cohort of 46 patients was categorised into three body mass index (BMI) groups: healthy, obese and overweight, and the patient’s weight from pre to post-36 cycles of Goserelin treatment was analysed and statistical change was calculated. Discussion: Initial findings suggested there was a huge variation in weight as the patient’s treatment progressed – this was either a weight gain (53% of patients) or a weight loss (47% of patients) as illustrated in Figure 1. When the statistical analysis was applied, however, there was no statistically significant relationship between BMI on commencing treatment and that at the end of 36 cycles of treatment. Conclusion: Weight is a well-documented risk factor in the development of cancer and in the successful treatment of cancers generally. Whilst this study did not show a statistically significant relationship between weight gain and treatment, further investigation is still warranted with a larger cohort size as it remains a major risk factor for poor health and cancer presentation or recurrence.1,2 [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
